Alicia Cazorla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alicia Cazorla has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Ana Osorio
Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
9 shared publications - Maria Jose Garcia
Computational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
6 shared publications Carmen Rivas
5 shared publicationsJavier Benítez
Human Genetics Group, Spanish National Cancer Research Center (CNIO), C/ Melchor Fernández Almagro 3, 28029, Madrid, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER), Spain
5 shared publications- Emiliano Honrado
Anatomical Pathology Service, Hospital de León, León, Spain
4 shared publications Enrique Lerma
Department of Human Genetics, Spanish National Cancer Centre, Madrid, Spain
4 shared publications
Latest Publications
- Open Access
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. In recent years, reactivation of the adaptive immune system in patients with solid tumors has emerged as a therapeutic option with great potential for clinical benefit. Since the approval of the first treatment directed against HER2 as a therapeutic target, the range of clinical options has expanded greatly, and, in this sense, cellular immunotherapy with T cells relies on the cytotoxicity generated by these cells, which ultimately leads to antitumor activity. Lymphocytic infiltration of tumors encompasses a heterogeneous population of immune cells within the tumor microenvironment that exhibits distinct patterns of immune activation and exhaustion. The prevalence and prognostic value of tumor-infiltrating lymphocyte (TIL) counts are associated with a favorable prognosis in HER2-positive breast cancers. This review discusses emerging findings that contribute to a better understanding of the role of immune infiltrates in HER2-positive breast cancer. In addition, it summarizes the most recent results in HER2-positive breast cancer immunotherapy and anticipates which therapeutic strategies could be applied in the immediate future.
Open AccessTumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of them are unresponsive to targeted therapies or they eventually relapse. In recent years, reactivation of the adaptive immune system in patients with solid tumors has emerged as a therapeutic option with great potential for clinical benefit. Since the approval of the first treatment directed against HER2 as a therapeutic target, the range of clinical options has expanded greatly, and, in this sense, cellular immunotherapy with T cells relies on the cytotoxicity generated by these cells, which ultimately leads to antitumor activity. Lymphocytic infiltration of tumors encompasses a heterogeneous population of immune cells within the tumor microenvironment that exhibits distinct patterns of immune activation and exhaustion. The prevalence and prognostic value of tumor-infiltrating lymphocyte (TIL) counts are associated with a favorable prognosis in HER2-positive breast cancers. This review discusses emerging findings that contribute to a better understanding of the role of immune infiltrates in HER2-positive breast cancer. In addition, it summarizes the most recent results in HER2-positive breast cancer immunotherapy and anticipates which therapeutic strategies could be applied in the immediate future.
- Open Access
- 1 June 2017
- Published by Elsevier in The Breast
- Vol. 33, 8-13
Role of total tumour load of sentinel lymph node on survival in early breast cancer patients
- 1 June 2017
- Published by Elsevier in The Breast
- Vol. 33, 8-13
Open AccessRole of total tumour load of sentinel lymph node on survival in early breast cancer patients
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 27 (1) , e7
The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients
Gayarre J, et al. J Gynecol Oncol. 2015 Nov;27(1):e7. https://doi.org/10.3802/jgo.2016.27.e7
- 1 January 2016
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 27 (1) , e7
Open AccessThe NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients
Gayarre J, et al. J Gynecol Oncol. 2015 Nov;27(1):e7. https://doi.org/10.3802/jgo.2016.27.e7
- 1 July 2015
- Published by Elsevier in Revista de Senología y Patología Mamaria
- Vol. 28 (3) , 113-119
Incidencia y seguimiento a 5 años de la recidiva locorregional durante 4 años consecutivos en una unidad multidisciplinar de patología mamaria
- 1 July 2015
- Published by Elsevier in Revista de Senología y Patología Mamaria
- Vol. 28 (3) , 113-119
Incidencia y seguimiento a 5 años de la recidiva locorregional durante 4 años consecutivos en una unidad multidisciplinar de patología mamaria
- Open Access
- 5 October 2014
- Published by Wiley in Molecular Oncology
- Vol. 9 (2) , 422-436
Deletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients
Standard treatments for advanced high‐grade serous ovarian carcinomas (HGSOCs) show significant side‐effects and provide only short‐term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin‐embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number‐based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03–0.81; Padj = 0.03). We found that loss at 6q24.2–26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01–0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48–0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61–0.90, log‐rank P = 0.002) and 675 high‐FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61–0.96, log‐rank P = 0.02) available from the online tool KM‐plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2–26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side‐effects and improve quality of life.
- 5 October 2014
- Published by Wiley in Molecular Oncology
- Vol. 9 (2) , 422-436
Open AccessDeletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients
Standard treatments for advanced high‐grade serous ovarian carcinomas (HGSOCs) show significant side‐effects and provide only short‐term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin‐embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number‐based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03–0.81; Padj = 0.03). We found that loss at 6q24.2–26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01–0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48–0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61–0.90, log‐rank P = 0.002) and 675 high‐FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61–0.96, log‐rank P = 0.02) available from the online tool KM‐plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2–26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side‐effects and improve quality of life.
- Open Access
- 4 April 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (8) , 1732-1742
DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and sporadic ovarian tumours. High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or specific copy number features. Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis, regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours. Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors.
- 4 April 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (8) , 1732-1742
Open AccessDNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and sporadic ovarian tumours. High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or specific copy number features. Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis, regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours. Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors.
- 1 March 2013
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 60 (3) , 149-151
Rinomucormicosis y diabetes mellitus tipo 1
- 1 March 2013
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 60 (3) , 149-151
Rinomucormicosis y diabetes mellitus tipo 1
- 1 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S146-S147
614 Characterization of Oncogenesis Process of Sporadic and Familial Epithelial Ovarian Cancer (EOC)
- 1 July 2012
- Published by Elsevier in European Journal of Cancer
- Vol. 48, S146-S147
614 Characterization of Oncogenesis Process of Sporadic and Familial Epithelial Ovarian Cancer (EOC)
- 17 October 2011
- Published by Wiley in Cytopathology
- Vol. 24 (2) , 81-84
Implementation of a joint protocol for the management of thyroid nodules with a cytological diagnosis of follicular lesion of undetermined significance: experience in one hospital
Background: Follicular lesion of undetermined significance (FLUS) was introduced for fine needle aspiration (FNA) cytology in which there is insufficient evidence to classify the lesion as follicular neoplasm/suspicious of follicular neoplasm or suspicious for malignancy. The recommended management was repeat FNA and correlation with clinical and radiological data. In 2009 we started a joint clinicopathological protocol to improve management of FLUS, recommending follow-up with repeat FNA at 6 months. The aim of this study was to report on the audit of results of this protocol. Methods: We reviewed the medical records of the patients with FLUS at a single hospital. Between 2007 and 2010 we found 135 cases with this diagnosis (3.6%). We only had long enough follow-up information for the 95 patients that were included in the present study. Results: FLUS was diagnosed in 74 FNAs before protocol implementation (3.2%) and 61 FNAs after (4.2%), with follow-up of 46 and 49 patients, respectively. Before 2009, 38/46 (82.6%) patients had surgical excisions, compared with 32/49 (65.3%): a significant reduction of 17% in the number requiring surgery (P = 0.05). We have also shown a reduction in the median time to surgery (11.9 versus 2.9 months). Despite the joint protocol, the FNA was only repeated in two patients. The histological diagnoses were similar in the two periods of time: 31.6% and 31.3% follicular adenomas; 13.1% and 3.1% (P = 0.2) papillary carcinoma (follicular variant). Conclusions: Implementation of a joint protocol reduced the number of surgical operations in patients with FLUS but in most cases FNA was not repeated as recommended. Excision was justified in one-third of operated patients. Less than 15% of lesions were malignant, which is in accordance with previous reports in the literature.
- 17 October 2011
- Published by Wiley in Cytopathology
- Vol. 24 (2) , 81-84
Implementation of a joint protocol for the management of thyroid nodules with a cytological diagnosis of follicular lesion of undetermined significance: experience in one hospital
Background: Follicular lesion of undetermined significance (FLUS) was introduced for fine needle aspiration (FNA) cytology in which there is insufficient evidence to classify the lesion as follicular neoplasm/suspicious of follicular neoplasm or suspicious for malignancy. The recommended management was repeat FNA and correlation with clinical and radiological data. In 2009 we started a joint clinicopathological protocol to improve management of FLUS, recommending follow-up with repeat FNA at 6 months. The aim of this study was to report on the audit of results of this protocol. Methods: We reviewed the medical records of the patients with FLUS at a single hospital. Between 2007 and 2010 we found 135 cases with this diagnosis (3.6%). We only had long enough follow-up information for the 95 patients that were included in the present study. Results: FLUS was diagnosed in 74 FNAs before protocol implementation (3.2%) and 61 FNAs after (4.2%), with follow-up of 46 and 49 patients, respectively. Before 2009, 38/46 (82.6%) patients had surgical excisions, compared with 32/49 (65.3%): a significant reduction of 17% in the number requiring surgery (P = 0.05). We have also shown a reduction in the median time to surgery (11.9 versus 2.9 months). Despite the joint protocol, the FNA was only repeated in two patients. The histological diagnoses were similar in the two periods of time: 31.6% and 31.3% follicular adenomas; 13.1% and 3.1% (P = 0.2) papillary carcinoma (follicular variant). Conclusions: Implementation of a joint protocol reduced the number of surgical operations in patients with FLUS but in most cases FNA was not repeated as recommended. Excision was justified in one-third of operated patients. Less than 15% of lesions were malignant, which is in accordance with previous reports in the literature.
- 1 September 2011
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 29 (5) , 545-549
Immunohistochemistry for the differential diagnosis of renal tumors with oncocytic features
- 1 September 2011
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 29 (5) , 545-549
Immunohistochemistry for the differential diagnosis of renal tumors with oncocytic features